Phase 1b Evaluation of Procizumab (PCZ; AK1967) in Cardiogenic Shock Secondary to Acute Coronary Syndrome or Sepsis

The primary objective of this Phase 1b trial is to evaluate the safety and tolerability of **procizumab** (PCZ; AK1967) in patients experiencing **cardiogenic shock** due to either acute coronary syndrome (ACS) or sepsis. This is clinically relevant as cardiogenic shock is a life-threatening condition that requires immediate intervention, and understanding the safety profile of procizumab could inform future therapeutic strategies for managing this critical condition.

The clinical trial involves participants diagnosed with **cardiogenic shock** due to either acute coronary syndrome (ACS) or sepsis. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial specifically targets a vulnerable population, although the total number of participants has not been disclosed by the sponsor. Participants were selected based on their medical condition, and no specific lifestyle considerations such as diet or physical activity have been highlighted. The trial does not provide detailed information on key inclusion or exclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of **procizumab** (PCZ; AK1967) in patients experiencing **cardiogenic shock** due to either acute coronary syndrome (ACS) or sepsis. This is a Phase 1b trial, characterized by a randomized, double-blind, and controlled design, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is expected to commence recruitment on March 1, 2025, and is projected to conclude by March 31, 2027, spanning a total duration of approximately two years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The study will include multiple follow-up visits to monitor the participants' response to the treatment and to collect data on safety and efficacy. These visits will be scheduled at regular intervals throughout the trial period. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement will vary depending on the individual's response to the treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the treatment, withdrawal of consent by the participant, or any significant protocol deviations. The trial is conducted under strict ethical guidelines and regulatory standards to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 1, 2025, with an estimated completion date of March 31, 2027. The efficacy assessment will be conducted through a series of predefined endpoints, although specific primary and secondary endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the collection and analysis of efficacy data is consistent with clinical trial standards. The trial's design and execution will adhere to rigorous protocols to evaluate the therapeutic impact of the investigational product, ensuring that the results are scientifically valid and reliable.